One of the first Canadians to help test out the new made-in-Canada Ebola vaccine says the shot didn't feel much different from a regular flu shot.

Halifax resident Emily Sollows, 22, received the vaccination Thursday morning as part of a clinical trial being conducted by the Canadian Centre for Vaccinology.

The vaccine -- currently dubbed PSC1001 – is being injected into selected volunteers to see whether causes an effective infection-fighting response and is well tolerated.

Researchers will also be monitoring participants for side-effects, which are expected to be similar to those that can occur after flu vaccines, including soreness at the injection site and mild fever.

Sollows said she hasn't really felt any different since getting the shot Thursday.

"Right after, I felt totally fine. Yesterday evening, I felt a little feverish but it was nothing too serious. And today, I feel fine again," she told CTV News Channel.

Sollows said she jumped at the chance to be part of the study, which has been interesting to her so far.

"For me, it was just about being part of such a potentially historical and groundbreaking study," she said.

"And also, I'm a student so the money doesn't hurt either," she added.

Each participant will receive roughly $1,100 for taking part in the trial. They will need to check in with researchers who will monitor their vital sign checks and collect blood samples once a week for four weeks.

As well, urine and saliva samples will be collected and sent to the National Microbiology Laboratory in Winnipeg, where the vaccine was developed. Those taking part in the clinical trial have also been asked to keep a diary, to track their temperature and how they are feeling in general.

Health officials say recruiting participants hasn't been an issue; hundreds expressed interest within hours of the announcement of the study. The research team has already screened 60 volunteers between the ages of 18 and 65, with the aims of settling on 40 participants.